OpenAI's Sam Altman spoke frankly during an intimate dinner with reporters about the rocky debut of GPT-5 and the company’s ...

The company, which has been referred to as Merge Labs, is looking at an approach involving gene therapy that would modify ...

Microsoft (MSFT)-backed OpenAI's latest venture, Merge Labs, is looking to develop a novel gene therapy approach targeting brain cells. Read more here.

Over dinner, OpenAI CEO’s addressed criticism of GPT-5’s rollout, the AI bubble, brain-computer interfaces, buying Google ...

Sam Altman plans to support a brain computer interface startup to rival Neuralink, as OpenAI expands its AI and technology ...

The Trump administration has ended potential enforcement actions against dozens of tech firms and 165 corporations overall, ...

Investing.com -- OpenAI CEO Sam Altman revealed ambitious plans for the company’s future during a dinner with Verge reporters in San Francisco on Thursday, including potential trillion-dollar ...

OpenAI's CEO is reportedly raising funds for a brain implant startup that would directly compete with Elon Musk's Neuralink.

The U.S. economy is in a strange place. Inflation is stubborn at 2.7%, job growth numbers have been revised down, trade barriers are up, investment sentiment is dropping in some quarters like the ...

Four people living with severe paralysis, caused by conditions including amyotrophic lateral sclerosis and brainstem stroke, took part in the trial. One participant could only respond ...

OpenAI CEO Sam Altman is reportedly working to launch a new brain-to-computer interface company, Merge Labs, with early ...

OpenAI CEO Sam Altman is still talking like the future belongs to him, a week after the rollout of the company's latest model ...